Literature DB >> 2949582

Potential mechanisms explaining the risk of left ventricular hypertrophy.

E D Frohlich.   

Abstract

Major risk factors have been identified that enhance the chances of cardiovascular morbidity and mortality. These include such modifiable factors as hypertension, hyperlipidemia, obesity, diabetes mellitus, smoking and hyperuricemia. Other factors that also increase risk are not modifiable and include advancing age, male gender and black race. The development of left ventricular (LV) hypertrophy imposes another significant risk for increased morbidity and mortality. Development of LV hypertrophy may be produced by hemodynamic as well as nonhemodynamic mechanisms. Included in the latter group are some of the same factors that in and of themselves participate in the production of increased LV mass (i.e., aging, gender and race, obesity, coronary disease, diabetes and the underlying mechanisms that subserve the hypertensive disease). This article discusses the concept, drawn from clinical and experimental studies, that demonstrate that the additional increased risk of LV hypertrophy may be ascribed to loss of reserve cardiac function, accelerated atherosclerosis, development of abnormal cardiac rhythm secondary to ischemia, fibrosis or drug-induced hypokalemia, inherent predisposition to ventricular dysrhythmias and sudden death, risks directly or coincidentally related to associated diseases or perhaps even the paradoxical risk of beneficial antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2949582     DOI: 10.1016/0002-9149(87)90183-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Mineralocorticoid-receptor blockade in hypertensive patients during angiotensin-converting enzyme inhibition: effects on left ventricular mass.

Authors:  Robert M Carey; Alexander G Logan
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 2.  Regression of increased left ventricular mass by antihypertensives.

Authors:  C J Lavie; H O Ventura; F H Messerli
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Ventricular performance in spontaneously hypertensive rats (SHR) with reduced cardiac mass.

Authors:  T Natsume; M B Kardon; B L Pegram; E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  Family support and cardiovascular responses in married couples during conflict and other interactions.

Authors:  S D Broadwell; K C Light
Journal:  Int J Behav Med       Date:  1999

5.  Correction of physiological alterations of hypertension.

Authors:  E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

6.  Comparison of arrhythmias among different left ventricular geometric patterns in essential hypertension.

Authors:  Z Zheng; R Zhou; Q Liang
Journal:  J Tongji Med Univ       Date:  2001

7.  Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.

Authors:  F Steensgaard-Hansen; J E Carlsen
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 8.  Factors involved in the pathogenesis of hypertensive cardiovascular hypertrophy. A review.

Authors:  B Dahlöf
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.